drugset / Trial / NCT04803305

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305 ↗

Phase 1 Completed 18 enrolled Pfizer
RandomizedSequentialTriple-blindTreatment

Summary

Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.

Timeline

Start
2021-05-11
Primary completion
2022-04-14
Completion
2022-08-09

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs PF-06946860 200mg Q3W; Mean Difference (Final Values) -0.60 (90% CI -2.38 to 1.18) NCT04803305 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject ponsegromab Monoclonal antibody — Subcutaneous